1. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries
- Author
-
Molebogeng Xheedha Rangaka, Takashi Yoshiyama, Lucy Chesire, Solange Cavalcante, Holger J. Schünemann, Ibrahim Abubakar, Marieke J. van der Werf, Nobuyuki Nishikiori, Philip A. LoBue, Monica Sañé Schepisi, Robert J. Wilkinson, Anna H. van’t Hoog, Susana Marta Borroto Gutierrez, Lisa J. Nelson, Lisa D. Rotz, Margaret Gale-Rowe, Alwyn Mwinga, Sandra V. Kik, Marije Vonk Noordegraaf-Schouten, Diana Weil, Cynthia B.E. Chee, Andreas Reis, Dick Menzies, Mario C. Raviglione, Malgorzata Grzemska, Alberto Matteelli, Nathan Ford, Natalia Vezhnina, Helen R. Stagg, Saskia Den Boon, Chris Gilpin, Enrico Girardi, Jean-Pierre Zellweger, Guy B. Marks, Draurio Barreira, Ya Diul Mukadi, C. Robert Horsburgh, Knut Lönnroth, Mohamed Abdel Aziz, Andreas Sandgren, Annabel Baddeley, Richard E. Chaisson, Rolando Cedillos, Giovanni Sotgiu, Davide Mosca, Dennis Falzon, Surender Kumar Sharma, Erlina Burhan, Jay K. Varma, Ross J Harris, Mukund Uplekar, Haileyesus Getahun, Karin Weyer, Wim Vandevelde, Timothy R. Sterling, Alison D. Grant, Asker Ismayilov, Masoud Dara, Judith Bruchfeld, Darshini Govindasamy, Anouk M. Oordt-Speets, Ernesto Jaramillo, Constantia Voniatis, Christian Lienhardt, Un Yeong Go, Giovanni Battista Migliori, Elizabeth L. Corbett, Justin T Denholm, Femke van Kessel, Gerard De Vries, Tamara Tayeb, Katharina Kranzer, Other departments, and Global Health
- Subjects
Gerontology ,Thoracic ,Antitubercular Agents ,Antirheumatic Agents/therapeutic use ,HIV Infections ,Comorbidity ,Kidney Failure ,Drug Users ,Substance-Related Disorders/epidemiology ,Mass Screening ,Medicine ,Chronic ,Human Biology & Physiology ,Evidence-Based Medicine ,Latent tuberculosis ,biology ,Coinfection ,Medicine (all) ,Disease Management ,Homeless Persons ,Antirheumatic Agents ,Emigrants and Immigrants ,Health Personnel ,Humans ,Interferon-gamma Release Tests ,Isoniazid ,Kidney Failure, Chronic ,Latent Tuberculosis ,Practice Guidelines as Topic ,Prisoners ,Public Health ,Radiography, Thoracic ,Renal Dialysis ,Rifampin ,Risk Assessment ,Silicosis ,Substance-Related Disorders ,Transplant Recipients ,Tuberculin Test ,Tumor Necrosis Factor-alpha ,World Health Organization ,Pulmonary and Respiratory Medicine ,HIV Infections/epidemiology ,Ill-Housed Persons ,Latent Tuberculosis/diagnosis ,Perspectives ,medicine.drug ,Model organisms ,medicine.medical_specialty ,Tuberculosis ,Isoniazid/therapeutic use ,Antitubercular Agents/therapeutic use ,Immunology ,Tuberculin ,Infectious Disease ,Mycobacterium tuberculosis ,Silicosis/epidemiology ,Internal medicine ,Coinfection/epidemiology ,Kidney Failure, Chronic/epidemiology ,Mass screening ,Tumor Necrosis Factor-alpha/antagonists & inhibitors ,business.industry ,FOS: Clinical medicine ,Rifampin/analogs & derivatives ,medicine.disease ,biology.organism_classification ,bacterial infections and mycoses ,Rifapentine ,Radiography ,Transplantation ,business ,Rifampicin - Abstract
Latent tuberculosis infection (LTBI) is characterised by the presence of immune responses to previously acquired Mycobacterium tuberculosis infection without clinical evidence of active tuberculosis (TB). Here we report evidence-based guidelines from the World Health Organization for a public health approach to the management of LTBI in high risk individuals in countries with high or middle upper income and TB incidence of, Guidelines on LTBI for low TB incidence countries – essential element of the @WHO #EndTB strategy and TB elimination http://ow.ly/RW8xn
- Published
- 2021
- Full Text
- View/download PDF